PolyTherics and Celtic Pharma sign agreement to explore technologies for improved drug performance

NewsGuard 100/100 Score

PolyTherics Limited, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, and Celtic Pharma Development Services Bermuda Ltd, a subsidiary of Celtic Pharmaceutical Holdings LP, a global private equity investment fund focused on the biopharma industry, today announced that they have entered into a broad research collaboration agreement.

Under the terms of the agreement, PolyTherics’ proprietary drug modification technologies will be used to enhance certain of the innovative pharmaceutical products being developed by Celtic Pharma.

The parties plan jointly to develop and validate modifications of drugs submitted to the collaboration by Celtic Pharma, in order to improve their performance and assess their future development potential.

PolyTherics has substantial expertise in the targeted and selective modification of compounds for therapeutic and diagnostic application. Through the application of a platform of polymer-based technologies, it is developing compounds as drug candidates in both existing and emerging markets. With the growing commercial impact of biopharmaceutical products, and particularly next generation antibody fragments, PolyTherics is strongly positioned to address these opportunities. PolyTherics has revenue-generating research and development contracts in place with several companies and is in discussion with a number of others.

Dr Keith Powell, Chief Executive Officer of PolyTherics, said: “We view collaboration through partnership as fundamental to exemplifying the development potential of our proprietary technologies and fulfilling our strategy. The opportunity to collaborate with a high calibre, product-focused company such as Celtic Pharma is a significant milestone in the development of PolyTherics, and we are delighted to be working with Celtic Pharma on several of the products in their portfolio. We believe that our work together will show that PolyTherics’ proprietary technologies can be used to improve pharmaceutical products to increase their commercial value.”

Celtic Pharma currently has a portfolio of nine novel pharmaceutical products in clinical development across a range of therapeutic areas. Each product is being developed to address important unmet medical needs, and Celtic Pharma aims to move these products rapidly and effectively through clinical development to regulatory approval.

Dr Bill Henry, Managing Director - Global Head of CMC at Celtic Pharma, said: “We are excited about accessing the technology capability of PolyTherics through collaboration and exploring its potential impact on our product pipeline.”

www.polytherics.co.uk and www.celticpharma.com


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research explores the health benefits of resistant starch in plant-based diets